Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · Real-Time Price · USD
5.11
+0.03 (0.59%)
At close: Jun 10, 2025, 4:00 PM
5.06
-0.05 (-0.98%)
After-hours: Jun 10, 2025, 6:09 PM EDT
Y-mAbs Therapeutics Revenue
Y-mAbs Therapeutics had revenue of $20.90M in the quarter ending March 31, 2025, with 4.88% growth. This brings the company's revenue in the last twelve months to $88.66M, up 4.92% year-over-year. In the year 2024, Y-mAbs Therapeutics had annual revenue of $87.69M with 3.38% growth.
Revenue (ttm)
$88.66M
Revenue Growth
+4.92%
P/S Ratio
2.57
Revenue / Employee
$852,481
Employees
104
Market Cap
231.46M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
YMAB News
- 13 days ago - Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline - GlobeNewsWire
- 15 days ago - Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting - GlobeNewsWire
- 4 weeks ago - Y-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025 - GlobeNewsWire
- 4 weeks ago - Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments - GlobeNewsWire
- 4 weeks ago - Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®) - GlobeNewsWire
- 5 weeks ago - Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025 - GlobeNewsWire
- 6 weeks ago - Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting - GlobeNewsWire